Latest News - Clinical Trials

Monday, July 24, 2017 | Clinical Trials, Glaucoma, BioLight

BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert

BioLight Life Sciences announced successful results from its glaucoma insert VS101 (Eye-D latanoprost insert) phase 1/2a clinical trial, which demonstrated its ability to lower IOP for a 12-week perio…

Read the full story

Thursday, July 20, 2017 | Clinical Trials, Alimera Sciences

Positive Results Enable Alimera Sciences to Reduce Enrollment in Iluvien Registry Safety Study in the UK

Alimera Sciences announced that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has given final approval to reduce the size of its Iluvien Registry Safety…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, Glaucoma, Aerie Pharmaceuticals

Aerie Pharmaceuticals Reports Positive Roclatan Phase 3, 12-Month Topline Safety Results

Aerie Pharmaceuticals reported the successful 12-month safety results of the company’s “Mercury 1” phase 3 registration trial for its fixed-dose combination product candidate, Roclat…

Read the full story

Wednesday, July 19, 2017 | Clinical Trials, AMD, BioTime

Data From BioTime’s Phase 1/2a OpRegen Trial to be Presented at the 2017 AAO Annual Meeting

BioTime announced that an abstract related to the company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being …

Read the full story

Monday, July 17, 2017 | Clinical Trials, Spark Therapeutics

Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA

Spark Therapeutics announced that the FDA has accepted for filing the biologics license application (BLA) and granted priority review for voretigene neparvovec, an investigational, potential one-time …

Read the full story

Friday, July 14, 2017 | Clinical Trials, AMD

Spark Therapeutics Announces Publication of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec

Gene therapy company Spark Therapeutics announced that The Lancet has published phase 3 clinical trial data of voretigene neparvovec, an investigational, potential one-time gene therapy candidate for …

Read the full story

Monday, July 10, 2017 | Clinical Trials, Inotek Pharmaceuticals

Inotek Pharmaceuticals Phase 2 Fixed-Dose Combination Trial of Trabodenoson Shows No Clinical Advantage in IOP Reduction After 4 Weeks

Inotek Pharmaceuticals announced topline results of the phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma. The trial was designed to assess the benefit…

Read the full story

Thursday, June 29, 2017 | Clinical Trials, Aerpio Therapeutics

Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of AKB-9778 in Patients with DR

Aerpio Pharmaceuticals announced the initiation of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead cand…

Read the full story

Monday, June 26, 2017 | Cataract Surgery, Clinical Trials

Icon Bioscience Annouces FDA Acceptance of NDA Filing for DEXYCU, a Noval Drug Therapy for Treating Inflammation Associated with Cataract Surgery

Icon Bioscience announced that it has received notification from the FDA that the agency has accepted for filing the company’s recently submitted new drug application (NDA) for DEXYCU (IBI-10090…

Read the full story

Monday, June 26, 2017 | Clinical Trials

Verseon Reveals Preclinical Data on Novel Drug Candidates to Treat Diabetic Macular Edema

Verseon presented preclinical data on multiple novel drug candidates for the treatment of diabetic macular edema (DME) at the 2017 BIO International Conference in San Diego last week. Verseon is de…

Read the full story

Thursday, June 22, 2017 | Clinical Trials

Nemus Bioscience Reports on Impact of NB1111 on Tissues that Regulate IOP in an Animal Normotensive Ocular Model

Nemus Bioscience announced that tetrahydrocannabinol (THC) derived from NB1111, the proprietary Nemus prodrug of THC, achieved significant tissue concentrations in multiple compartments of the eye tha…

Read the full story

Thursday, June 22, 2017 | Clinical Trials, Retina, AMD

RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring

RXi Pharmaceuticals announced the completion of enrollment in its phase 1/2 study RXI-109-1501. This multicenter, multidose, dose escalation trial is being conducted in patients with advanced neovascu…

Read the full story

Wednesday, June 21, 2017 | Clinical Trials, Glaucoma, Glaukos Corporation

Study: Combining Implantation of Glaukos iStent inject with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile

Glaukos announced that a study of 53 open-angle glaucoma subjects recently published in Clinical & Experimental Ophthalmology showed that the iStent inject Trabecular Micro-Bypass, combined with t…

Read the full story

Tuesday, June 20, 2017 | Clinical Trials, AMD, Novartis

Novartis RTH258 (Brolucizumab) Demonstrates Robust Visual Gains in Wet AMD Patients with a Majority on a 12-week Injection Interval

Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints in two phase 3 studies, HAWK and HARRIER. RTH258 3 mg, evaluated in HAWK, also met these endpoints. These …

Read the full story

Tuesday, June 20, 2017 | Clinical Trials

Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia

Neurotech Pharmaceuticals, in collaboration with the Lowy Medical Research Institute (LMRI), announced 24-month results demonstrating that NT- 501 delivering Ciliary Neurotrophic Factor (CNTF) has a b…

Read the full story
Load More